Compare Summit Therapeutics Inc (SMMT) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while Vanguard Short Term Corporate Bond ETF trades at $78.52. The key difference: Summit Therapeutics Inc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| SMMT | VCSH | |
|---|---|---|
Market Cap | $12.06B | — |
Sector | Health | Fixed Income |
52-Week High | $26.98 | $80.20 |
52-Week Low | $12.55 | $78.41 |
Enterprise Value | $11.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
VCSH trades at $78.58, up 0.11% today, with a bearish technical signal from moving averages but neutral oscillators. The ETF maintains a 4.8% yield with recent dividends of $0.29-$0.30, though credit spreads are tight. News highlights institutional activity, including Apella Capital reducing its stake by 5.6% in Q2 2026 (SEC filing, August 7, 2026).
Outlook is cautious due to unattractive entry points and limited upside from rate cuts, per Seeking Alpha (July 27, 2026). Risks include credit spread widening and competition from alternatives like BSV. The short 2.7-year duration offers some downside protection, but yield advantages may narrow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
